LPCN News and Press, Lipocine Inc. From 06/14/21

Lipocine (LPCN) jumps 9% premarket after announcing that the FDA has cleared its IND application to initiate a Phase 2 study to evaluate the therapeutic potential of LPCN 1154, an oral neuro-steroid product candidate, for the treatment of postpartum depression ((PPD)) in adults. A p...

FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study PR Newswire SALT LAKE CITY , June 14, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today ...

Lipocine to Present at the Lytham Partners Summer 2021 Investor Conference PR Newswire SALT LAKE CITY , June 7, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today ...

Gainers: Owens & Minor (OMI) +25%.Express (EXPR) +23%.PDL Community Bancorp (PDLB) +22%.Takung Art (TKAT) +22%.Assertio Holdings (ASRT) +21%.Asensus Surgical (ASXC) +20%.Lizhi (LIZI) +20%.ReneSola (SOL) +19%.Arcimoto (FUV) +18%.Planet Green (PLAG) +16%.Losers: Lar...

Larimar Therapeutics (LRMR) -40% after FDA puts clinical hold on CTI-1601 program.GSX Techedu (GOTU) -15% after Q1 earnings releaseCarLotz (LOTZ) -16% after losing key sourcing partner temporarily.Travere Therapeutics (TVTX) -13% on sparsentan developme...

Summary Judgment Ruling in Patent Infringement Lawsuit PR Newswire SALT LAKE CITY , May 26, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the...

The U.S. District Court of Delaware has granted Clarus Therapeutics' motion for summary judgment against Lipocine (LPCN) for failure to provide adequate written description of Lipocine's asserted patent claims.In his decision, which gives Clarus an unequivocal win, Judge William C. Bryson fou...

Clarus Therapeutics Defeats Lipocine's Patent Infringement Lawsuit On Summary Judgment US District Court for the District of Delaware grants Clarus's Motion for Summary Judgment against remaining patents in patent infringement case brought by Lipocine, Inc. regarding Clarus's or...

Lipocine (LPCN): Q1 GAAP EPS of -$0.04 beats by $0.01.Unrestricted cash, cash equivalents, and marketable investments of $50.0M.Press Release For further details see: Lipocine EPS beats by $0.01

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021 PR Newswire SALT LAKE CITY , May 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, to...